Scientists modeled tumor-specific MEK inhibition (MEKi) through CRISPR/Cas-mediated genome editing of tumor cells and pharmacologic MEKi with cobimetinib in a RAS-driven model of colorectal cancer.
[Cancer Immunology Research]
6445218
{6445218:AG4ZDHX4}
apa
50
1
165744
https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/
%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3A%22zotpress-3069cf32d5e5f7d1b85be7cdbcd807a7%22%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%22AG4ZDHX4%22%2C%22library%22%3A%7B%22id%22%3A6445218%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Dennison%20et%20al.%22%2C%22parsedDate%22%3A%222021-01-01%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EDennison%2C%20L.%2C%20Ruggieri%2C%20A.%2C%20Mohan%2C%20A.%2C%20Leatherman%2C%20J.%2C%20Cruz%2C%20K.%2C%20Woolman%2C%20S.%2C%20Azad%2C%20N.%2C%20Lesinski%2C%20G.%20B.%2C%20Jaffee%2C%20E.%20M.%2C%20%26amp%3B%20Yarchoan%2C%20M.%20%282021%29.%20Context-Dependent%20Immunomodulatory%20Effects%20of%20MEK%20Inhibition%20are%20Enhanced%20with%20T-cell%20Agonist%20Therapy.%20%3Ci%3ECancer%20Immunology%20Research%3C%5C%2Fi%3E.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1158%5C%2F2326-6066.CIR-21-0147%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1158%5C%2F2326-6066.CIR-21-0147%3C%5C%2Fa%3E%20%3Ca%20title%3D%27Cite%20in%20RIS%20Format%27%20class%3D%27zp-CiteRIS%27%20href%3D%27https%3A%5C%2F%5C%2Fwww.stemcellsciencenews.com%5C%2Fwp-content%5C%2Fplugins%5C%2Fzotpress%5C%2Flib%5C%2Frequest%5C%2Frequest.cite.php%3Fapi_user_id%3D6445218%26amp%3Bitem_key%3DAG4ZDHX4%27%3ECite%3C%5C%2Fa%3E%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Context-Dependent%20Immunomodulatory%20Effects%20of%20MEK%20Inhibition%20are%20Enhanced%20with%20T-cell%20Agonist%20Therapy%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lauren%22%2C%22lastName%22%3A%22Dennison%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Amanda%22%2C%22lastName%22%3A%22Ruggieri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aditya%22%2C%22lastName%22%3A%22Mohan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22James%22%2C%22lastName%22%3A%22Leatherman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kayla%22%2C%22lastName%22%3A%22Cruz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Skylar%22%2C%22lastName%22%3A%22Woolman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nilofer%22%2C%22lastName%22%3A%22Azad%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gregory%20B.%22%2C%22lastName%22%3A%22Lesinski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elizabeth%20M.%22%2C%22lastName%22%3A%22Jaffee%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mark%22%2C%22lastName%22%3A%22Yarchoan%22%7D%5D%2C%22abstractNote%22%3A%22MEK%20inhibition%20%28MEKi%29%20is%20proposed%20to%20enhance%20antitumor%20immunity%20but%20has%20demonstrated%20mixed%20results%20as%20an%20immunomodulatory%20strategy%20in%20human%20clinical%20trials.%20MEKi%20exerts%20direct%20immunomodulatory%20effects%20on%20tumor%20cells%20and%20tumor-infiltrating%20lymphocytes%2C%20but%20these%20effects%20have%20not%20been%20independently%20investigated.%20Here%20we%20modeled%20tumor-specific%20MEKi%20through%20CRISPR%5C%2FCas-mediated%20genome%20editing%20of%20tumor%20cells%20%28MEK1%20KO%29%20and%20pharmacologic%20MEKi%20with%20cobimetinib%20in%20a%20RAS-driven%20model%20of%20colorectal%20cancer.%20This%20approach%20allowed%20us%20to%20distinguish%20tumor-mediated%20and%20tumor-independent%20mechanisms%20of%20MEKi%20immunomodulation.%20MEK1%20KO%20tumors%20demonstrated%20upregulation%20of%20JAK%5C%2FSTAT%20signaling%3B%20enhanced%20MHCI%20expression%2C%20CD8%2B%20T-cell%20infiltration%20and%20T-cell%20activation%3B%20and%20impaired%20tumor%20growth%20that%20is%20immune-dependent.%20Pharmacologic%20MEKi%20recapitulated%20tumor-intrinsic%20effects%20but%20simultaneously%20impaired%20T-cell%20activation%20in%20the%20tumor%20microenvironment.%20We%20confirmed%20a%20reduction%20in%20human%20peripheral%20lymphocyte%20activation%20from%20a%20clinical%20trial%20of%20anti-PD-L1%20%28atezolizumab%29%20with%20or%20without%20cobimetinib%20in%20biliary%20tract%20cancers.%20Impaired%20activation%20of%20tumor-infiltrating%20lymphocytes%20treated%20with%20pharmacologic%20MEKi%20was%20reversible%20and%20was%20rescued%20with%20the%20addition%20of%20a%2041BB%20agonist.%20Collectively%2C%20these%20data%20underscore%20the%20ability%20of%20MEKi%20to%20induce%20context-dependent%20immunomodulatory%20effects%20and%20suggest%20that%20T%20cell-agonist%20therapy%20maximizes%20the%20beneficial%20effects%20of%20MEKi%20on%20the%20antitumor%20immune%20response.%22%2C%22date%22%3A%222021%5C%2F01%5C%2F01%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1158%5C%2F2326-6066.CIR-21-0147%22%2C%22ISSN%22%3A%222326-6066%2C%202326-6074%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fcancerimmunolres.aacrjournals.org%5C%2Fcontent%5C%2Fearly%5C%2F2021%5C%2F08%5C%2F13%5C%2F2326-6066.CIR-21-0147%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222021-08-17T00%3A20%3A05Z%22%7D%7D%5D%7D
Dennison, L., Ruggieri, A., Mohan, A., Leatherman, J., Cruz, K., Woolman, S., Azad, N., Lesinski, G. B., Jaffee, E. M., & Yarchoan, M. (2021). Context-Dependent Immunomodulatory Effects of MEK Inhibition are Enhanced with T-cell Agonist Therapy. Cancer Immunology Research. https://doi.org/10.1158/2326-6066.CIR-21-0147 Cite
